Introduction
Fibroblast growth factor receptors (FGFRs), consisting of four genes named FGFR1-FGFR4, are one of the subfamilies of receptor tyrosine kinases (RTKs) (1) . Eighteen different FGF ligands bind to the distinct FGFRs or their alternative splicing isoforms through formation of ternary complexes with heparan sulfate proteoglycans (2), FGFRs regulate important physiological processes including cell growth, and their dysregulated activities are implicated in various human diseases. For example, FGFR1 overexpression resulting from 8p12 amplification induces carcinogenesis in the breast (3) , and is implicated in 22% of squamous cell lung cancers (4) . About 15-20% of multiple myeloma patients are caused by overexpression of FGFR3 within strong IgH enhancers as a result of a t(4;14)(p16.3;q32. 3) chromosomal translocation (5) . In 60-70% of non-muscle-invasive superficial bladder cancers, gain of function FGFR3 mutations such as S249C/Y373C in the extracellular region and mutations of K650 in the kinase domain are indicative of a high risk for tumor recurrence (6) . In addition, a FGFR3-ETV6 fused gene generated by a t(4;12)(p16;p13) chromosomal translocation causes peripheral T-cell lymphoma (7) . FGFR1-TACC1 and FGFR3-TACC3 fused genes are associated with glioblastoma multiforme (8) . Overexpression of FGFR4 has been shown to be associated with 7-8% of rhabdomyosarcoma, which is the most common soft tissue sarcoma in children (9, 10) . Moreover, FGFR1-3 mutations found in cancers are also involved in various skeletal disorders such as Apert syndrome and Crouzon syndrome (11) (12) (13) . About 10-12% of endometrial cancers (ECs) are associated with constitutively active FGFR2 mutants (14, 15) , where S252W mutation in the extracellular domain increases the binding affinity with FGF and N550K mutant in the kinase domain loosens the auto-inhibitory conformation (13, 16) . Despite mutations of the both PI3K pathway and FGFR2, FGFR2 inhibition alone using siRNA FGFR2 knockdown or small molecule inhibitors blocks the growth of ECs harboring PTEN/FGFR2 mutations, while it shows no effect in HEC1A
ECs expressing wild-type FGFR2 along with PTEN/KRAS mutations (17, 18 ).
Owing to their prominent roles in cancers, FGFRs have become significant targets for inhibitor development (19). This effort has led to discovery of several FGFR inhibitors including dovitinib, BGJ398, ponatinib, LY2874455, and AZD4547, all of which have entered clinical trials as potential anti-cancer drugs. As a frontrunner in the group of pan-FGFR inhibitors, AZD4547 was demonstrated to promote favorable therapeutic outcomes against a variety of FGFR-deregulated cancer models, including glioblastoma, non-small-cell lung cancer (NSCLC), gastric cancer, and multiple myeloma (20-23). However, little is known about the efficacy of AZD4547 against FGFR2 mutant-driven endometrial cancer.
Here, we investigated detailed anti-cancer mechanism of AZD4547 against FGFR2-mutant expressing endometrial cancers.
Materials and Methods

Reagents
Inhibitors including AZD4547, BGJ398, sorafenib, dasatinib, and cabozantinib, are purchased form Sellek Chemicals. Recombinant human acidic FGF (aFGF) was from R&D Systems (#231-BC). Heparin sulfate (#H3149), collagen (#C7661), and iodonitrotetrazolium chloride (#I8377) were from Sigma Aldrich. Antibodies for FGFR2, actin, phospho-GSK3β (Ser9), caspase 3, and cleaved PARP were purchased from Santa Cruz Biotechnology. Other primary antibodies were purchased from Cell Signaling Technology: phospho-FGFR (Tyr653/654, #3471), phospho-FRS2α (Tyr436, #3861), phospho-ERK1/2 (Thr202/Tyr204, #4370), phospho-AKT (Thr308, #4056; Ser473, #4058), phospho-JNK (Thr183/Tyr185, #4668), phospho-p38 (Thr180/Tyr182, #4511), phospho-RET (Tyr905, #3221), phospho-FLT3 (Tyr591, #3474), phospho-DDR1 (Tyr792, #11994), phospho-FMS (Tyr723, #3155), phospho-PLK1 (Thr210, #9062), phosphor PLCγ (Tyr783, #2821), phospho-STAT1 (Tyr701, #9167), phospho-STAT3 (Ser727, #9134), phospho-p70S6K (Thr421/Ser424, #9204), phospho-CREB (Ser133, #9198), phospho-IκB (Ser32/36, #9246), FGFR1 (#9740),
FLT3(#3462), RET (#3220), AKT (#4685), ERK (#4695), HSP60 (#4870), EGR1 (#4153).
Antibodies for immunohistochemistry were anti-Ki67 (Leica) anti-phospho-S6 (S235/236), (cell signaling #2211) anti-cleaved caspase3 (cell signaling #9661).
Cell culture
MFE280, MFE296, and MOLM-14 cells were purchased from DSMZ. TT, MV4-11, U2OS, AN3-CA, and HEC1A cells were purchased from ATCC. Ishikawa cells were purchased from Sigma-Aldrich. Every cell line was used within 6 months after their DNA profiles were confirmed with short tandem repeat (STR) analysis by Korean Cell Line Bank. AN3-CA (endometrium), Ishikawa (endometrium), and HEK293T cells were maintained in DMEM supplemented with 10% FBS and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). HEC1A cells were cultured in DMEM/F12 media supplemented with 10% FBS and antibiotics. MFE280 (endometrium) and MFE296 (endometrium) cells were maintained in a RPMI1640/MEM (1:1) supplemented with 20 % FBS and antibiotics. TT cells (medullary thyroid) were cultured in RPMI 1640 media supplemented with 2 mM 10 points of 3-fold serial dilution (0 -50 μM). For adherent cells, cells were treated with compounds one day after cell seeding. After 72 h exposure, cell viability was measured using 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium (MTT) assay kit (Promega). Each assay was performed in duplicate mode three independent times. Cell viability of compound-treated wells was normalized relative to 0.5% DMSO-treated wells (100%). GI 50 values were calculated using Prism 5.0 software (Graphpad).
Apoptosis and Cell cycle analysis
For apoptosis assay, cells were treated with AZD4547 and BGJ398 for 48 h. All floating and attached cells were harvested by trypsinization and washed with phosphate buffered saline (DPBS pH 7.4). Cells were stained using an annexin-V-FLUOS staining kit (Roche, # 11 988 549 001). For cell cycle analysis, cells were treated with compounds for 24 h and harvested as above and fixed in 70% ethanol at -20 °C overnight. Cells were harvested by centrifugation at 500g, washed with cold DPBS, then suspended in propidium iodide/RNase solution (Cell Signaling, #4087) and incubated for 30 min in a dark condition before flow cytometer analysis (BD Biosciences).
Soft agar assay
On the 0.5% bottom agar, cells in the complete media containing 0.3% agar was plated at a density of 2,000 cells in 6-well plates. The plates were incubated for 3 weeks at 37 °C and 5% CO 2 . Compounds diluted in culture media were added on the top agar. Media was refreshed twice a week. Spheroids were stained using iodonitrotetrazolium chloride (Sigma Aldrich) for 24 h. The entire area of each well was photographed without magnification, and colonies in each well were counted using Image J software.
Phospho-kinase array analysis
AN3-CA cells serum-starved media (DMEM containing 0.5% FBS) overnight were treated with either DMSO or AZD4547 (300 nM) for 2 h. Cells were stimulated with 10 ng/mL aFGF and 10 μg/mL heparin sulfate for 20 min. Cells were then lysed and subjected to the analysis using human-phosphokinase array kit (R&D Systems) using the manufacturer's protocol.
Reporter gene assay
Reporter gene assays were conducted using a Cignal 45-pathway reporter assay kit (SABiosciences) following the manufacturer's protocol. Eighteen hours after transfection, media in each plate was changed to Opti-MEM containing DMSO, DMSO plus aFGF (10 ng/mL), or AZD4547 (1 μM) plus aFGF (10 ng/mL). After 24 h, Dual-Glo luciferase assay reagents (Promega) were added. Luminescence values were normalized by dividing firefly emission by renilla emission as Relative Luminescence Units (RLUs). RLU values related to DMSO controls were represented as fold changes.
Microarray analysis
AN3-CA cells were treated in three different conditions for 18 h; 1) DMSO (0.5%) only, 2) co-treatment of aFGF (10 ng/ml) and DMSO (0.5%), and 3) co-treatment of aFGF (10 ng/ml) and AZD4547 (300 nM) in duplicate mode and then lysed with 1 mL of Trizol reagent (Life Technologies). Total mRNAs were isolated using RNeasy Mini Kit (QIAGEN, CA) and were subjected to GeneChip PrimeViewTM Human Gene Expression Array (Affymetrix). Station 450. GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G. The data were analyzed using Robust Multi-array Analysis (RMA) with Affymetrix default analysis settings and global scaling as the normalization method. The trimmed mean target intensity of each array was arbitrarily set to 100. The normalized and log transformed intensity values were then analyzed using GeneSpring GX 12.6 (Agilent technologies). Fold change filters included the requirement that the genes be present in at least 150% of controls for up-regulated genes and lower than 66% of controls for down-regulated genes.
Hierarchical clustering data were clustered into groups that behave similarly across experiments using GeneSpring GX 12.6.1 (Agilent technologies). This microarray data was deposited in GEO public repository (GEO accession no. GSE61481).
RT-PCR
Total RNAs were extracted from cells treated with the indicated condition using Trizol reagent (Invitrogen) according to the manufacturer's instruction. Total RNAs (2 μg) was used to synthesize cDNA with M-MLV reverse transcriptase (Promega). Equal amount of cDNA was amplified with PCR for 30 cycles. The exact size of amplified PCR products was assessed by electrophoresis in 3% agarose gels and visualized by Eco-star dye (Biofect #ES301-1000). Primer sequences are listed in Supplementary Table S1 . 
Gene set enrichment analysis (GSEA)
We utilized 509 gene sets publicly available in molecular signature database (MSigDB) as described (25). These gene sets are categorized by transcription factor binding motif in their promoter regions. For each gene set, we calculated enrichment score to evaluate the distribution of members of a given gene set throughout total gene list. Enrichment score (ES) means the maximum distance form X axis in the enrichment plot, and high ES reflects that a gene set is overrepresented at the top of the entire list. Variation in gene set size was adjusted in normalized ES (NES). False discovery rate (FDR) reflects the probability of false positive interpretation of the gene set with NES. 
Xenograft model
Results
AZD4547 displays anti-proliferative effects against FGFR2 mutant expressing endometrial cancer cells.
We measured the kinase-inhibitory activities of AZD4547 against WT FGFR1-4 and their mutants (Table 1) Based on the potent kinase-inhibitory activity against the N550H-FGFR2 mutant (IC 50 = 8 nM), we measured the antiproliferative activity of AZD4547 against endometrial cancer cell lines harboring FGFR2 activating mutants (Table 1) . We also included HEC1A
ECs expressing normal FGFR2. AZD4547 strongly suppressed the proliferation of AN3-CA cells harboring the FGFR2 double mutant K310R/N550K with the GI 50 value of 31 nM.
MFE296 (GI 50 = 730 nM) cells and MFE280 (GI 50 = 218 nM) cells, harboring N550K-FGFR2 and S252W-FGFR2 respectively, were about 7 to 20-fold less sensitive to AZD4547.
On the other hand, endometrial cancer cells with other FGFR2 aberration such as Ishikawa (FGFR2 overexpression) and HEC1A (normal FGFR2) cells were resistant to AZD4547. This implicates that AZD4547 was highly effective to FGFR2 activating mutant-addicted ECs.
Biochemical kinase profiling of AZD4547 against a large panel of kinases and evaluation of its cellular activities
The 3-amidopyrazole based structure of AZD4547 ( (Table 1) .
We then examined antiproliferative activities using kinase-transformed Ba/F3 cell lines and human cancer cell lines (Table 1) and RET, while it does not inhibit DDR1 in cell.
AZD4547 inhibits the proliferation of AN3-CA cells by mainly targeting FGFR2
We also assessed the inhibitory effects of AZD4547 against FLT3, DDR1, RET, FMS, and MELK in AN3-CA and HEC1A cells. We examined the phosphorylation of PLK1 to evaluate MELK cellular activity (26). AZD4547 at 0.1 μM almost completely inhibited phosphorylation of FRS2α (Y436) in AN3-CA cells, whereas it showed no inhibition of p-FRS2α in HEC1A cells (Fig. 1D) . On contrary, phosphorylation of were not inhibited at the same dosage. These results suggest that AZD4547 inhibited FGFR2 mutant-driven endometrial cancer cells mainly through inhibition of FGFR2.
We then assessed the cellular activity of AZD4547 in AN3-CA, MFE296, and HEC1A cells for inhibition of FGFR signaling. In order to activate FGFR2 pathway in ECs, we used aFGF as a ligand. Meanwhile, it is of note that aFGF can activate all FGFR isotypes, and both AN3-CA and MFE296 cells reportedly contain almost equal gene copy number for each FGFR isotype (27). Time course experiments showed that AZD4547 at 1 μM quickly inhibited the phosphorylations of FGFR (Y653/654) and ERK1/2 (T202/Y204) in AN3-CA and MFE296 cells, but attenuated phospho-AKT only in AN3-CA cells. In contrast, none of those signaling molecules were affected by 1 μM AZD4547 in HEC1A cells (Fig. 1E) . It was also observed that phospho-ERK1/2 level in AN3-CA and MFE296 cells was increased at late time due to negative feedback mechanism. In addition, aFGF-induced phosphorylations of various FGFR downstream proteins including PLCγ (Y783), FRS2α (Y436), AKT (T308), and ERK1/2 (T202/Y204) were attenuated by AZD4547 in a dose-dependent manner in AN3-CA and MFE296 cells, not in HEC1A cells (Fig. 1F ).
AZD4547 induces G1/S arrest and apoptosis, and inhibits colony formation of AN3-CA cells
We next examined the effects of AZD4547 on cell cycle and apoptosis using AN3- affect the cell cycle of HEC1A cells ( Fig. 2A) . Also, FACS analysis showed that treatment of either compound for 48 h induced apoptosis in AN3-CA and MFE296 cells, whereas it did not induce apoptosis in HEC1A cells (Fig. 2B) . Upregulation of cleaved PARP was observed in AN3-CA and MFE280 cells (Fig. 2C) . We also observed enhancement of p53 transcription activity by AZD4547 (1 μM) in AN3-CA cells, suggesting that AZD4547 promoted apoptosis and cell cycle arrest through activation of p53 (Fig. 2D) . Furthermore, we evaluated the effect of AZD4547 on anchorage-independent growth of the three cell lines using soft agar assay (Fig. 2E) . Treatment with AZD4547 (0.3 μM or 1 μM) for 3 weeks almost completely blocked the formation of the colonies of AN3-CA and MFE296 cells, while it did not block the colony formation of HEC1A cells harboring normal FGFR2.
AZD4547 inhibits multiple signalings including JNK and ERK1/2 in ECs
We then used a phospho-kinase array to find which signaling pathways are blocked by AZD4547 in AN3-CA cells. AZD4547 at 300 nM attenuated the aFGF-induced phosphorylations of p38 (T180/Y182), ERK1/2 (T202/Y204, T185, Y187), JNK (T183/Y185, T221/Y223), CREB (S133), p70S6K (T421/S424), STAT3 (Y705), and PLCγ (Y783) (Fig.   3A ). We performed western blot analysis using AN3-CA cells and confirmed that phosphorylations of PLCγ, p70S6K, JNK, ERK1/2, and p38 were blocked by AZD4547 (Fig.   3B ). We repeated the same analysis using MFE296, MFE280, and HEC-1A cells as well. 
9) in AN3-CA and MFE296 cells (Supplementary Fig. S2 ). This suggests that the activity of AZD4547 might be related mainly with its ability to block MAPK pathways.
AZD4547 perturbs various transcription factors including SRF/Elk-1 and AP-1
Next, we performed 45 pathway dual-reporter gene assays to investigate which transcription factors were affected by AZD4547 in AN3-CA cells. Among 45 transcription factors, four transcription factors were significantly (p<0.05) perturbed by AZD4547 (Fig.   3C ). Reporter activities (firefly/renilla) of STAT1/2 and NF-κB were observed to be downregulated by aFGF, and antagonized by AZD4547. In contrast, the transcriptional activity of AP1 and SRF/Elk-1 were upregulated by aFGF stimulation, and AZD4547 blocked the upregulation of AP1 and SRF/Elk-1. The perturbations of these four transcription factors were verified by measuring the phospho-levels of the transcription factors or their upstream regulators (Fig. 3D) . Western blot analysis showed that phosphorylations of JNK, ERK1/2, and IκBα, which are well-known upstream regulators of AP-1, Elk-1, and NF-κB respectively, were enhanced by aFGF, and were antagonized by AZD4547. Likewise, phosphorylation of STAT1 was down-regulated by aFGF stimulation, and was antagonized by AZD4547.
AZD4547 changes the transcriptions of a number of genes including EGR1
In addition, we carried out a genome-wide transcriptome analysis using AN3-CA cells. AN3-CA cells were treated with vehicle (DMSO only), with vehicle and aFGF (DMSO+aFGF), or with AZD4547 and aFGF (AZD4547+aFGF). RNAs were harvested at 18 h post-treatment and analyzed using Affymetix Primeview arrays (Fig. 4A) . We identified that 143 probes were up-regulated more than 2 fold by aFGF stimulation relative to DMSO 
only (p<0.01), and that 240 probes were significantly down-regulated less than 0.5 fold after co-treatment of aFGF and AZD4547 relative to (aFGF+DMSO) treatment (p < 0.01) (Supplementary Table S3 and S4). Thus, we assumed that all 143 genes overlapped in both probe sets would be the FGFR downstream target genes (Fig. 4B and Supplementary Table   S5 ). To validate the microarray results, reverse transcription (RT)-PCR was performed for six randomly selected genes including EGR1, THBS1, SERTAD1, and SERPINE1 among the 143 genes (Fig. 4C) , and GAPDH was used as a normalization control. Consistent with microarray results, all six genes were upregulated by aFGF stimulation and restored to basal levels by AZD4547 (0.3 μM).
We carried out gene set enrichment analysis (GSEA) to interpret microarray data (25).
We found that 95 gene sets, out of 509 gene sets from transcription factor-binding sequence elements in MSigDB (molecular signatures database), were significantly enriched at the top rank of genes down-regulated by AZD4547 (FDR < 0.25, p < 0.01). A gene set with SRFbinding motif (named SRF gene set hereafter) showed the highest enrichment score, followed by EGR1-3 and PAX3 gene sets. The enrichment plot of SRF-binding genes and EGR1
binding genes showed that their gene members were highly concentrated in top tier of the entire gene list with NES value of 2.08 and 1.59, respectively (Fig. 4D ). This implies that target genes of SRF and EGR1 were significantly down-regulated by (aFGF+AZD4547) treatment compared to (aFGF+DMSO). EGR1 also bears SRF binding promoter near its transcription initiation site (27). We investigated whether EGR1 plays an important role in mutant FGFR2 mediated cancer progression of ECs. Time-course stimulation of aFGF in AN3-CA cells showed that EGR1 level was rapidly increased within 1 h, and maintained throughout the course (Fig. 4E) . In addition, attenuation of FGFR2 phosphorylation through siRNA knockdown or AZD4547 treatment resulted in suppression of aFGF-mediated EGR1 upregulation, and AZD4547 displayed more dramatic EGR1 downregulation than FGFR2 siRNA (Fig. 4F) . These results indicate that EGR1 expression level is controlled by FGFR signaling.
AZD4547 causes remarkable delay of tumor growth in AN3-CA mouse xenograft model
The in vivo efficacy of AZD4547 was also examined using mouse xenograft models where AN3-CA cells are grafted through s.c. injection (Fig. 5A ). AZD4547 displayed a dosedependent anti-tumor efficacy. While the average tumor volume of the vehicle-treated group (n = 7) was observed to increase to around 1000 mm 3 , the AZD4547 treated (10 mg/kg, orally once a day) group (n = 7) delayed the tumor growth and shrink the tumor volume to 360 mm 3 .
Moreover, the group (n = 7) treated with 30 mg/kg AZD4547 further delayed the tumor growth and almost reached tumor regression within a week. In addition, AZD4547 did not reduce significantly the bodyweight of AZD4547-treated group, which implicated that its cytotoxic effect might be negligible (Fig. 5B) . We performed immunohistochemistry staining using paraffin-embedded tumor sections from a mouse administered for 14 days, and found that the levels of pERK1/2, and pS6, and Ki67 were greatly downregulated and the level of cleaved caspase 3 was enhanced by AZD4547 (30 mpk), which indicates that AZD4547 also effectively blocked the FGFR signalings and induced cancer cell apoptosis in vivo (Fig. 5C ).
We also observed that the level of EGR1 was also decreased in AZD4547-adminstrated mouse, confirming EGR1 downregulation by AZD4547 in vivo. Our study suggests that EGR1 downregulation is related to AZD4547's efficacy against ECs.
We also showed that AZD4547 suppressed anchorage independent growth of AN3-CA cells and induced significant tumor regression in AN3-CA mouse xenograft model in conjunction with a significant decrease in proliferation markers including p-ERK1/2 and Ki67 in tumors. The efficacy of AZD4547 might be associated with the findings from unbiased reporter gene assays and transcriptome analysis using AN3-CA cells. AZD4547
perturbed the activities of a number of transcription factors such as EGR-1 and SP1 which are related to proliferation as well as up-regulating p53 activity.
We here report the detailed mechanism by which AZD4547 expresses its anti-cancer effect against FGFR2 mutant-dependent endometrial cancer cells. Our study demonstrates that AZD4547 exhibits its therapeutic activity against endometrial cancer cells by perturbing 
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